Reviewing Connect Biopharma (NASDAQ:CNTB) & Northwest Biotherapeutics (OTCMKTS:NWBO)

Northwest Biotherapeutics (OTCMKTS:NWBO) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Northwest Biotherapeutics and Connect Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Northwest Biotherapeutics	0	0	0	0	0.00
Connect Biopharma	1	0	6	1	2.88

Connect Biopharma has a consensus price target of $7.17, suggesting a potential upside of 199.86%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Northwest Biotherapeutics.

Institutional & Insider Ownership

0.0% of Northwest Biotherapeutics shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 2.4% of Northwest Biotherapeutics shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Northwest Biotherapeutics and Connect Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Northwest Biotherapeutics	-2,931.73%	N/A	-79.26%
Connect Biopharma	N/A	-122.29%	-97.07%

Earnings & Valuation

This table compares Northwest Biotherapeutics and Connect Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Northwest Biotherapeutics	$1.38 million	222.37	-$60.16 million	($18.23)	-0.01
Connect Biopharma	$60,000.00	2,507.91	-$55.48 million	($1.15)	-2.08

Connect Biopharma has lower revenue, but higher earnings than Northwest Biotherapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Northwest Biotherapeutics has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500.

Summary

Connect Biopharma beats Northwest Biotherapeutics on 11 of the 15 factors compared between the two stocks.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.